Bli medlem
Bli medlem

Du är här

2016-10-26

Novasep: NOVASEP ANNOUNCES THE SUCCESS OF ITS REFINANCING

Not for direct or indirect release, publication or distribution in the United
States, Australia, Canada or Japan.

News release

Lyon, France, October 26, 2016

NOVASEP ANNOUNCES THE SUCCESS OF ITS REFINANCING

* Successful outcome of Exchange Offer and Consent Solicitation
* Participation of 96.26% of the principal amount of Existing Notes held by
holders other than Novasep or its Affiliates

Novasep Holding S.A.S ("Novasep
"), a leading supplier of manufacturing solutions for the life science
industries, is pleased to announce that the exchange offer and consent
solicitation that was launched on September 26, 2016 (the "Exchange Offer and
Consent Solicitation
") for the purpose of refinancing its outstanding 8.00% Senior Secured Notes
due 2016 in the aggregate principal amount of $195,164,000 (the "Existing
Notes
") has achieved a successful outcome. The Exchange Offer and Consent
Solicitation expired at 5:00 p.m., New York City time, on October 25, 2016
(the "Expiration Date
").

The Existing Notes are currently listed on the Official List of the Luxembourg
Stock Exchange and admitted to trading on the Euro MTF market (ISIN numbers:
XS0737680479 / XS0737712181).

The successful completion of the Exchange Offer and Consent Solicitation was
subject to a participation threshold of at least 90% of the outstanding
principal amount of the Existing Notes held by persons other than Novasep or
any of its "Affiliates" (as defined in the indenture relating to the Existing
Notes). As of the Expiration Date, the participation rate was 96.26% of the
total outstanding principal amount of Existing Notes held by holders other
than Novasep or Affiliates of Novasep.

This success fuels Novasep's growth plan and will make available to Novasep
additional resources to capture the potential of major trends in the life
sciences industries, in particular gene therapy/immunotherapy, monoclonal
antibodies and antibody-drug conjugates (ADCs).

Michel Spagnol, Novasep's CEO and Chairman, said:

"I am delighted that our shareholders and bondholders have confirmed their
confidence in Novasep's management team and its strategy. We currently
observe very good dynamics in most of our main markets and notably in the
biologics segment, which is an area of key focus for Novasep. In addition, we
are seeing many investments in the food ingredient industry. Our improved
financial structure will enable us to bring new services to our customers
over the coming years.
"

The Exchange Offer and Consent Solicitation will close, and the Exchange
Consideration (as defined in Novasep's exchange offer and consent
solicitation statement dated September 26, 2016 (the "Exchange Offer
Memorandum
")) will be paid, on or about November 3, 2016. The payment of the Exchange
Consideration includes the issuance of the Exchange Notes and the Warrants
and the payment of the Cash Payment (in each case, as defined in the Exchange
Offer Memorandum).

THE EXCHANGE OFFER MEMORANDUM AND ALL RELATED DOCUMENTATION ARE AVAILABLE UPON
REQUEST AND FREE OF CHARGE FROM LUCID ISSUER SERVICES LIMITED, THE EXCHANGE
AND INFORMATION AGENT (THE "EXCHANGE AGENT") FOR THE TRANSACTION, OR AT THE
COMPANY'S HEADQUARTERS.

About Novasep

Novasep is a global provider of cost-effective and sustainable manufacturing
solutions for life sciences molecules and fine chemicals. Novasep's unique
offering includes process development services, purification equipment and
turnkey processes, contract manufacturing services and complex active
molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and
functional ingredients as well as fermentation and chemical commodities
industries.
www.novasep.com

Analyst contact

Communication Contact: Brunswick

69 Boulevard Haussmann
75008 Paris
France

Agnès Catineau / +33 153 968 383
Nathalie Baudon / +33 153 968 376
novasep@brunswickgroup.com

Information and exchange agent:

Lucid Issuer Services Limited

Tankerton Works
12 Argyle Walk
London WC1H 8HA
United Kingdom
+ 44 20 7704 0880
novasep@lucid-is.com
Attention: Thomas Choquet / Sunjeeve Patel

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy securities. There will not be any sale of securities in
any such state or country in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any state or country. The issue, the subscription for or the purchase of the
securities referred to herein may be subject to specific legal or regulatory
restrictions in certain jurisdictions. Novasep assumes no responsibility for
any violation of any such restrictions by any person.

The securities referred to herein have not been and will not be registered
under the US Securities Act of 1933 (the "Securities Act
") and may not be offered and sold in the United States absent registration or
an applicable exemption from the registration requirements of the Securities
Act.

This press release is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States or any other
jurisdiction. The securities referred to herein may not be offered or sold
in the United States unless registered under the Securities Act or pursuant
to an exemption from such registration. Such securities have not been, nor
will be, registered under the Securities Act. Any offer of securities in the
United States would be made by means of a prospectus that could be obtained
from the issuer and that would contain detailed information about the company
and its management as well as incorporating certain financial statements.

The distribution of this document in certain countries may constitute a breach
of applicable law. The information contained in this document does not
constitute an offer of securities for sale in Canada, Australia or Japan.
This press release may not be published, forwarded or distributed, directly
or indirectly, in the United States, Canada, Australia or Japan.

Click here for PDF version
http://hugin.info/173227/R/2051748/767744.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novasep via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.